BOSTON, Aug. 24, 2011 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that the Company has been included on the "Best 5–Pharmaceutical" industry sublist as part of The International Association of Outsourcing Professionals® (IAOP®) annual ranking The Global Outsourcing 100.
IAOP is in the sixth year of compiling its annual ranking of the world's best outsourcing service providers and advisors. The Global Outsourcing 100 and its sublists are valued references for companies seeking new and expanded relationships with the best companies in the industry. The independently-judged evaluation process considers four key criteria: size and growth, customer experience, depth and breadth of competencies and management capabilities.
"The companies on The Global Outsourcing 100 list are proven leaders and rising stars," said IAOP Chairman Michael Corbett and chair of the judges' panel. "They are the companies to partner with to achieve success and better outsourcing outcomes."
"PAREXEL is honored to be selected for the 'Best 5–Pharmaceutical' industry sublist by the judges of The Global Outsourcing 100," said Josef von Rickenbach, Chairman and Chief Executive Officer of PAREXEL International. "The biopharmaceutical industry is exploring new ways to address key time and cost challenges through more effective outsourcing, while achieving more efficient development and commercialization of important new treatments. At PAREXEL, a key focus is to deliver high levels of quality and best-practice outsourcing models to create significant value for our clients."
About IAOP The International Association of Outsourcing Professionals® (IAOP®) is the global, standard-setting organization and advocate for the outsourcing profession. With more than 110,000 members and affiliates worldwide, IAOP helps companies increase their outsourcing success rate, improve their outsourcing ROI, and expand the opportunities for outsourcing across their businesses. To learn more, visit http://www.iaop.org.
About PAREXEL InternationalPAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has approximately 10,550 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated restructuring charge of approximately $18 million over the fourth quarter of Fiscal Year 2011 as well as the first and second quarters of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2011 as filed with the SEC on May 10, 2011, which "Risk Factors" discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.Contacts:Jennifer Baird, Senior Director of Public Relations
Kim Baker/Gene CarozzaPAREXEL International
PAN CommunicationsTel: +781-434-4409
Tel: + 617-502-4300Email: Jennifer.Baird@PAREXEL.com
|SOURCE PAREXEL International Corporation|
Copyright©2010 PR Newswire.
All rights reserved